Heren Health Co Ltd

Heren Health maintains a strong liquidity position with a current ratio of 3.77, indicating the company can cover its short-term obligations more than three times over. The company's liquidity_fpt score of 0.82 suggests a solid cash position relative to its peers, though its free cash flow of 21.8 million CNY is modest compared to operating cash flow of 125.9 million CNY.

Profitability metrics show a return on equity of 4.14% and a return on assets of 3.18%, both below the industry median of 5.2% and 4.5%, respectively. The company's gross margin of 46.6% is in line with the industry median, but its operating margin of 12.0% is slightly below the median of 13.5%, indicating potential inefficiencies in cost control.

Geographically, Heren Health's revenue is concentrated in China, with no material international operations disclosed. The company operates in a single business segment focused on medical imaging equipment, with no diversification into other healthcare services or products.

The company's revenue growth is projected to remain flat in the current fiscal year, with a slight decline expected in the next fiscal year. Historical revenue growth has averaged 8.5% annually, but recent performance has slowed to 3.2% year-over-year, reflecting market saturation and increased competition.

Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk with no near-term pressure from share issuance. The company's debt-to-equity ratio of 0.05 is well below the industry median of 0.25, indicating a conservative capital structure.

Recent filings and transcripts show no material changes in business strategy or financial outlook. The company continues to invest in R&D for next-generation MRI systems, with a focus on improving image resolution and reducing scan times.